Author

J. de Bono

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Approach:experimental assay· 1 Approach:genetic perturbation / CRISPR· 1 Organism:human· 1 Organism:mouse· 1

Frequent Co-Authors

A. Califano· 1 shared A. Juncker-Jensen· 1 shared A. Vasciaveo· 1 shared B. D. Robinson· 1 shared B. Gurel· 1 shared C. Abate-Shen· 1 shared C. Bailey· 1 shared C. E. Lewis· 1 shared

Activity by Year

2023-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Califano

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Targeting of a STING Agonist to Perivascular Macrophages in Prostate Tumors Delays Resistance to Androgen Deprivation Therapy

H. Al-janabi, K. Moyes, R. J. Allen, M. Fisher, M. Crespo, B. Gurel, P. Rescigno, J. De Bono, H. Nunns, C. Bailey, A. Juncker-Jensen, M. Muthana, W. A. Phillips, H. Pearson, M.-E. Taplin, , C. E. Lewis

This study shows targeting a STING agonist to perivascular macrophages in ADT-treated prostate tumors delays castration resistance prostate cancer onset.

bioRxiv · Apr 11, 2024Cancer Biology

NSD2 maintains lineage plasticity and castration-resistance in neuroendocrine prostate cancer

J. J. Li, A. Vasciaveo, D. Karagiannis, Z. Sun, X. Chen, F. Socciarelli, Z. Frankenstein, M. Zou, T. Pannellini, Y. Chen, K. Gardner, B. D. Robinson, J. de Bono, C. Abate-Shen, M. A. Rubin, , M. M. Shen

This study identifies NSD2 as a key driver of lineage plasticity and castration-resistance in neuroendocrine prostate cancer, showing its inhibition can restore sensitivity to AR inhibitors.

bioRxiv · Jul 18, 2023 · PreprintCancer Biology